First Look at Gilead Drug Virus Response to Open Data Floodgates

The first look at how well Gilead’s Ebola drug treats Covid-19 patients in an NIH clinical trial should come in a matter of weeks, the agency’s head said Monday.

If available, that initial analysis would come a little more than two months after the trial began. It’s also the first wave in a deluge of data the National Institutes of Health and the Food and Drug Administration will need to assess as they aggressively shepherd new medicines to treat the viral outbreak.

The data won’t just come from closely controlled clinical trials like for Gilead’s remdesivir but also from ...